Komori

Materials for the briefing on financial results for the second quarter (interim period) of the fiscal year ending March 2027

Results presentationFirst half, FY ending Mar 2027Published 2026-11-19 18:00

The drug discovery support business secured 4 contracts and recorded ¥16 million in business revenue. However, operating loss widened by ¥40 million from the same period of the previous year due to higher R&D expenses, including those associated with the Phase 3 clinical trial of RBM-007.

In short

Forecast raised
  • The drug discovery support business secured 4 contracts and recorded ¥16 million in business revenue.
  • Operating loss was ¥578 million due to higher R&D expenses.
  • A total of 18 patients have been enrolled in the Phase 3 ACH trial of RBM-007, exceeding the required 16 patients.

What they reported

this period against the same period a year earlier, and where they now expect the year to end

Sales

¥16.0m
FY25FY26FY27 · this year0510¥mQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4this yearvs same quarter last yearnew forecast5.0 a quarterlast yearold forecast0.5 a quarter
Sales by quarter
Period¥m
FY25 Q11.0
FY25 Q21.0
FY25 Q30.0
FY25 Q40.0
FY26 Q43.0
FY27 Q14.0
FY27 Q212.0
last year 3.0
was 17.0
now 26.0
Full-year forecast, ¥m+52.9% vs the old forecast
Old and new forecast from the company's results releases
Why

The drug discovery support business secured 3 joint research contracts and 1 outsourcing contract and recorded ¥16 million in business revenue.

創薬支援事業において、共同研究契約3件、業務委託契約1件の計4件の契約獲得を通じて、事業収益16百万円を計上。
In the drug discovery support business, ¥16 million in business revenue was recorded through the acquisition of 4 contracts, comprising 3 joint research contracts and 1 outsourcing contract.

Operating profit

−¥0.6bnloss widenedvs a year earlier
H1 FY26−¥0.5bnH1 FY27−¥0.6bn
FY25FY26FY27 · this year-1-0-0-0¥bnQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4▼this yearvs same quarter last yearlast yearnew forecast-0.4 a quarterold forecast-0.5 a quarter
Operating profit by quarter
Period¥bn
FY25 Q1-0.3
FY25 Q2-0.3
FY25 Q3-0.3
FY25 Q4-0.3
FY26 Q1-0.2
FY26 Q2-0.3
FY26 Q3-0.3
FY26 Q4-0.4
FY27 Q1-0.3
FY27 Q2-0.3
last year -1.2
was -1.5
now -1.5
Full-year forecast, ¥bnloss narrowed vs the old forecast
Old and new forecast from the company's results releases
Why

Higher expenses, including those associated with the start of the Phase 3 clinical trial, led to a wider operating loss.

将来の事業成長に向け、ACH:第3相臨床試験開始に伴う研究開発活動を着実に推進。研究開発費は46百万円増加し、当期純損失は547百万円となりました。
To support future business growth, activities related to the start of the Phase 3 clinical trial of ACH are being steadily advanced. R&D expenses increased by ¥46 million, and net loss was ¥547 million.

Ordinary profit

−¥0.5bnloss widenedvs a year earlier
H1 FY26−¥0.5bnH1 FY27−¥0.5bn
FY25FY26FY27 · this year-0-0-0¥bnQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4▼▲this yearvs same quarter last yearlast year
Ordinary profit by quarter
Period¥bn
FY25 Q1-0.3
FY25 Q2-0.2
FY25 Q3-0.3
FY25 Q4-0.3
FY26 Q1-0.2
FY26 Q2-0.3
FY26 Q3-0.2
FY26 Q4-0.4
FY27 Q1-0.3
FY27 Q2-0.3

Net profit

−¥0.5bnloss widenedvs a year earlier
H1 FY26−¥0.5bnH1 FY27−¥0.5bn
FY25FY26FY27 · this year-1-0-0-0¥bnQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4▼▲this yearvs same quarter last yearlast yearnew forecast-0.5 a quarterold forecast-0.5 a quarter
Net profit by quarter
Period¥bn
FY25 Q1-0.3
FY25 Q2-0.2
FY25 Q3-0.3
FY25 Q4-0.3
FY26 Q1-0.2
FY26 Q2-0.3
FY26 Q3-0.2
FY26 Q4-0.4
FY27 Q1-0.3
FY27 Q2-0.3
last year -1.1
was -1.5
now -1.4
Full-year forecast, ¥bnloss narrowed vs the old forecast
Old and new forecast from the company's results releases
Why

Net loss was ¥547 million due to higher R&D expenses and other factors.

研究開発費は46百万円増加し、当期純損失は547百万円となりました。
R&D expenses increased by ¥46 million, and net loss was ¥547 million.

Their own numbers

figures this company chose to report, a year ago against now
Number of contracts in the drug discovery support business
4 transactions

The company secured 3 joint research contracts and 1 outsourcing contract.

Number of corporate partnerships
6 transactions

As of October 2026, 6 partnerships in Japan and overseas are indicated.

Number of enrollees in the Phase 3 ACH trial
18 people

A total of 18 patients have been enrolled, exceeding the 16 patients required for the Phase 3 trial.

Number of medical institutions conducting the Phase 3 ACH trial
16 facilities

The clinical trial is being conducted at 16 institutions.

Maximum enrollment in the Phase 3 ACH trial
25 peopleFY27 plan

The maximum number of enrollees is stated to be 25.

The low–high ranges are Komori's estimate, not figures the company gave.

Everything else in the deck

What moved

change vs a year earlier, by the company's own breakdown
Operating income
Business revenue+¥16.0m
Increase in R&D expenses−¥46.0m
Increase in selling, general and administrative expenses−¥10.0m
Bar colour is the direction of the amount (red = up, teal = down).

New initiatives

what they said they're starting
  • The company transitioned to a company with an Audit and Supervisory Committee and launched a new management team.
  • The company added a drug discovery support business using a DDS aptamer system as a new business model.
  • The company is advancing the development of novel DDS aptamer technologies, including aptamer-modified LNPs.
  • The company is pursuing partnerships with companies in Japan and overseas through its DDS aptamer system.
  • The company started a Phase 3 clinical trial of RBM-007 for achondroplasia.

What decks usually leave out

COMPUTED = worked out by Komori from reported numbers; the rest are stated in this deck

Progress toward the full-year forecast

share of the year's target already earned, against the same point in past years
Computed
62%of the sales forecast earned
with 50% of the year gone: within the range of the last 3 years (5%–100%)
Operating profit isn't shown: the company forecasts a loss this year, so progress isn't a share of it.
50% of the year gone
FY23
5%
FY24
52%
FY25
100%
FY27
62%
how much of the year has gonepast-year average at this point (52%)

¥16.0m earned of the ¥26.0m forecast. Against the old forecast (¥17.0m) it would be 94%.

The rest of the year has to bring in ¥10.0m, +9 pts off the usual pace.

Progress toward the full-year forecast
Period%
FY235%
FY2452%
FY25100%
FY2762%

Margins and overheads

where each ¥100 of sales goes
Computed
Operating margin
-3612.5%

Financial targets

the last five years against the target (green band), where one is stated
Computed
Return on equity-54.4%
profit earned on shareholders' money
−15.5 pts on last year
-56%-40%-24%FY22FY23FY24FY25FY26FY27FY22: -31.5%FY23: -36.4%FY24: -26.3%FY25: -31.6%FY26: -38.9%FY27: -54.4% (forecast)-54.4%
Return on equity
Period%
FY22-31.5
FY23-36.4
FY24-26.3
FY25-31.6
FY26-38.9
FY27-54.4
Equity ratio94.3%
how much of the balance sheet is owned outright
−1.1 pts on last year
92%95%98%FY22FY23FY24FY25FY26FY27FY22: 94.7%FY23: 95.7%FY24: 95.5%FY25: 95.5%FY26: 95.4%FY27: 94.3%94.3%
Equity ratio
Period%
FY2294.7
FY2395.7
FY2495.5
FY2595.5
FY2695.4
FY2794.3

Yearly figures are computed by Komori from J-Quants results data (ROE = net profit ÷ average equity). The last point is this year's forecast or latest figure. Targets show only when this deck states them.

Mid-term plan targets

VISION 2030

The deck refers to this plan, but no numeric targets were read from it.

Market size and share

square area = market size · a year ago outlined, now filled
Number of patients eligible for ACH treatment in the United States and Europe
The number of ACH patients is indicated as 8,000, and the total number of patients, including HCH, as 16,000.
market
8,000people

The company's slice (blue) is drawn magnified so a small share stays visible; compare it with its own dashed outline from a year ago.

Not mentioned in this deck

13
By businessCapital spendingShare buybackDividendSelf-rating against planForecast assumptionsRisks priced into the forecastA stated financial targetOrders and backlogPrice and volumeStore or site countHeadcountInvestor Q&A
Materials for the briefing on financial results for the second quarter (interim period) of the fiscal year ending March 2027 | RIBOMIC Inc. (4591) timely disclosure | Komori